CD19 and acute lymphoblastic leukemia: CAR-T cells have shown promising results in the treatment of hematologic malignancies and are being used mainly to treat cancers for which the primary target is CD19, i.e., B-cell lymphoma, childhood acute lymphoblastic leukemia (ALL), and adult-onset ALL.